Hetrombopag Olamine
Phase 3Small molecule
Hetrombopag Olamine is a small molecule that works as a Thrombopoietin Receptor Agonist.[2] It is being investigated across 5 indications, with its most advanced program in Phase 3.[1]
Hetrombopag Olamine is one of 100 small molecule programs targeting Severe Aplastic Anemia. It is currently in Phase 3.
5
Indications
18
Total Trials
5
Active Trials
99
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
255 competitors in Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Idamycin
PfizerPhase 3
Novantrone
PfizerPhase 3
Xospata
AstellasPhase 3
Cerubidine
EEastern Cooperative Oncology Group
Phase 3
Vepesid
AAvyxa
Phase 3
Mylotarg
WWyeth-Lederle Vaccines
Phase 3
Vanflyta
Daiichi SankyoPhase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Nexavar
BayerPhase 3
Trexall
Jazz PharmaceuticalsPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Thrombocytopenic Purpura3 trials
Severe Aplastic Anemia3 trials
Tics2 trials
Thrombocytopenia2 trials
7 more indications
Immune Tolerance1 trial
Acute Myeloid Leukemia1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Hetrombopag Olamine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details